A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
NCT07218380
This study is recruiting at 40 US sites in 19 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to test a new medicine, vepugratinib, in comparison with placebo, to see if it is safe and can help people with a bladder cancer that is advanced or has spread. Vepugratinib or placebo will be administered in combination with enfortumab vedotin and pembrolizumab. Study participation could last up to approximately 6 years.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Carcinoma, Transitional Cell
- Urinary Bladder Neoplasms
- Neoplasm Metastasis
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Eli Lilly and Company
- Last updated on ClinicalTrials.gov
- October 7, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Arizona · 1
- The University of Arizona Cancer Center - North Campus · Tucson, AZ
California · 7
- Chao Family Comprehensive Cancer Center and Ambulatory Care (CIACC) - Irvine · Irvine, CA
- TRIO-US (Translational Research in Oncology-US) · Los Angeles, CA
- UCLA Hematology/Oncology - Santa Monica · Los Angeles, CA
- University of California, Irvine (UCI) Health - UC Irvine Medical Center · Orange, CA
- University of California Davis (UC Davis) Comprehensive Cancer Center · Sacramento, CA
- UCSF Medical Center at Mission Bay · San Francisco, CA
- Hunt Cancer Institute, an Affiliate of Cedars-Sinai Cancer (TMPN) · Torrance, CA
Colorado · 1
- Colorado West Healthcare System - Grand Valley Oncology · Grand Junction, CO
Illinois · 1
- University of Illinois at Chicago · Chicago, IL
Indiana · 3
- Parkview Research Center at Parkview Regional Medical Center · Fort Wayne, IN
- Franciscan Health · Indianapolis, IN
- Indiana University Melvin and Bren Simon Cancer Center · Indianapolis, IN
Louisiana · 2
- Mary Bird Perkins Cancer Center · Baton Rouge, LA
- Mary Bird Perkins Cancer Center - Metairie · Metairie, LA
Maryland · 1
- Johns Hopkins Hospital · Baltimore, MD
Michigan · 1
- Karmanos Cancer Institute · Detroit, MI
Missouri · 2
- Oncology Hematology Associates · Springfield, MO
- Washington University School of Medicine · St Louis, MO
Nevada · 1
- Comprehensive Cancer Centers of Nevada · Las Vegas, NV
New Jersey · 1
- Astera Cancer Care · East Brunswick, NJ
New York · 2
- Columbia University Irving Medical Center · New York, NY
- Memorial Sloan Kettering Cancer Center · New York, NY
North Carolina · 1
- Oncology Specialists of Charlotte · Charlotte, NC
Oregon · 3
- Kaiser Permanente Interstate Medical Office Central · Portland, OR
- Providence Portland Medical Center · Portland, OR
- Providence St. Vincent Medical Center · Portland, OR
Pennsylvania · 1
- AHN Allegheny General Hospital · Pittsburgh, PA
South Dakota · 1
- Avera Cancer Institute- Research · Sioux Falls, SD
Tennessee · 3
- Sarah Cannon Research Institute · Nashville, TN
- SCRI Oncology Partners · Nashville, TN
- Tennessee Oncology · Nashville, TN
Texas · 7
- USO-Texas Oncology-Central/South Texas · Austin, TX
- World Research Link · Baytown, TX
- UT Southwestern Medical Center · Dallas, TX
- University of Texas MD Anderson Cancer Center · Houston, TX
- Nova Oncology · McAllen, TX
- US Oncology Research Network · The Woodlands, TX
- USO - Texas Oncology - Northeast Texas · Tyler, TX
Virginia · 1
- USO - Virginia Oncology Associates · Norfolk, VA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.